Do we like Jonas Salk?
Our score: 9 out of 10. He gave away a life-saving vaccine and has no harmful words on record, with only some old credit-grabbing grumbles from fellow scientists.
Jonas Salk was a researcher who built on earlier work on inactivated flu vaccines, and he worked with Thomas Francis Jr. on the first flu vaccine. He then took on the polio fight at a time when the common belief was that only live viruses could give lasting immunity. His killed-virus polio vaccine was announced on 12 April 1955 and made him an international hero.
The famous bit is the patent. Asked on television by Edward R. Murrow who owned it, Salk replied that there was no patent and asked if you could patent the sun. The Washington Post's Brian Palmer later noted that foundation lawyers had concluded the vaccine did not meet the novelty requirements for a patent, and that the foundation had already handed its production methods to drug companies for free. So the line oversimplifies a bit, but nobody has shown Salk was being dishonest.
Not everyone loved him. Time's retrospective says many scientists criticised him for testing in secret, and some accused him of not crediting other researchers and of chasing media attention. One of his own backers said the scientific community acted as if he had committed a felony. The biographer behind that account thought the picture of a glory-seeking dilettante was distorted, so call it a contested stain rather than a pattern.
On the harm test he is clean: we found no slur, no campaign against any group and no conspiracy talk in the coverage we read. He was a vaccine man through and through, which is about as far from anti-vax grievance as you can get. In an interview with Bill Moyers he talked about humans being part of nature and about vaccines teaching the body to remember. He later helped found a company working on an HIV vaccine that did seek a patent, which Palmer saw nothing wrong with.
He also had a stoush with the next generation. Salk opposed the US shift to Albert Sabin's live oral vaccine, warning that a weakened live virus could revert to a virulent form. His late-career HIV work split opinion, with some calling it a desperate bid to recover former glory and others finding his ideas ingenious. That is an honest scientific disagreement, not a character flaw.
Nothing new on him lately: no fresh controversy turned up, just anniversary pieces and retrospectives. The only live issue is how his no-patent stance gets used today. Palmer called it a rallying cry against pharmaceutical profiteering, and a dangerous shortcut that sidesteps the hard question of how to reward medical breakthroughs.